Meeting
2018 ASCO Annual Meeting
An amplicon-based liquid biopsy for detecting ALK and ROS1 fusions and resistance mutations in advanced non-small cell lung cancer (NSCLC) patients.
Authors
Laura Mezquita
Department of Cancer Medicine, Gustave Roussy Cancer Campus, Paris-Sud University, Villejuif, France
Laura Mezquita , Cecile Jovelet , Ludovic Lacroix , David Planchard , Gonzalo Recondo , Emma Pailler , Edouard Auclin , Vincent Plagnol , Karen Howarth , Clive D. Morris , Emma Green , Etienne Rouleau , Claudio Nicotra , Caroline Caramella , Julien Adam , Nathalie Auger , Francoise Farace , Luc Friboulet , Benjamin Besse
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 36, 2018 (suppl; abstr 9095)
DOI
10.1200/JCO.2018.36.15_suppl.9095
Abstract #
9095
Poster Bd #
418
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Phase 3 trial of lorlatinib in treatment-naive patients (Pts) with ALK-positive advanced non–small cell lung cancer (NSCLC): Comprehensive plasma and tumor genomic analyses.
First Author: Alessandra Bearz
Poster
2023 ASCO Annual Meeting
Mechanisms of resistance to tyrosine kinase inhibitor treatments in patients with ROS1 fusion-positive non-small cell lung cancer.
First Author: Jialei Wang
Poster
2023 ASCO Annual Meeting
Utility of ctDNA tumor fraction to inform negative liquid biopsy (LBx) results and need for tissue reflex in advanced non-small cell lung cancer (aNSCLC).
First Author: Christian Diego Rolfo
Poster
2017 ASCO Annual Meeting
Genomic profiling of circulating tumor DNA (ctDNA) from patients (pts) with advanced non-small cell lung cancer (NSCLC).
First Author: Ibiayi Dagogo-Jack